Macrogenics (MGNX) Common Equity (2012 - 2026)

Macrogenics (MGNX) has 15 years of Common Equity data on file, last reported at $21.2 million in Q1 2026.

• On a quarterly basis, Common Equity fell 73.21% year-over-year to $21.2 million in Q1 2026; TTM through Mar 2026 was $21.2 million, a 73.21% decrease from a year earlier, with the FY2025 full-year figure at $55.6 million, down 52.1% from the prior year.
• Common Equity for Q1 2026 stood at $21.2 million, down from $55.6 million in the prior quarter.
• Over the last five years, Common Equity for MGNX reached as high as $194.0 million in Q3 2023 and fell as low as $21.2 million in Q1 2026.
• Historically, Common Equity has averaged $110.7 million across 5 years, with a median of $116.1 million in 2024.
• Across the five-year window, Common Equity surged 57.76% in 2023 and sank 73.21% in 2026, its largest moves.
• Year by year, Common Equity stood at $142.0 million in 2022, then advanced by 7.46% to $152.6 million in 2023, then fell by 23.95% to $116.1 million in 2024, then tumbled by 52.1% to $55.6 million in 2025, then tumbled by 61.87% to $21.2 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $21.2 million in Q1 2026, $55.6 million in Q4 2025, and $67.0 million in Q3 2025.